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Abstract The mTORC1 inhibitor everolimus (Afinitor/RAD001) has been approved for
multiple cancer indications, including ER+/HER2− metastatic breast cancer. However, the
combination of everolimus with the dual PI3K/mTOR inhibitor BEZ235 was shown to be
more efficacious than either everolimus or BEZ235 alone in preclinical models. Herein, we
describe a male breast cancer (MBC) patient who was diagnosed with hormone receptor-
positive (HR+)/HER2− stage IIIA invasive ductal carcinoma and sequentially treated with
chemoradiotherapy and hormonal therapy. Upon the development of metastases, the
patient began a 200 mg twice-daily BEZ235 and 2.5 mg weekly everolimus combination
regimen. The patient sustained a prolonged stable disease of 18 mo while undergoing the
therapy, before his tumor progressed again. Therefore, we sought to both better
understand MBC and investigate the underlying molecular mechanisms of the patient’s
sensitivity and subsequent resistance to the BEZ235/everolimus combination therapy.
Genomic and immunohistochemical analyses were performed on samples collected from
the initial invasive ductal carcinoma pretreatment and a metastasis postprogression on the
BEZ235/everolimus combination treatment. Both tumors were relatively quiet genomically
with no overlap to recurrent MBC alterations in the literature. Markers of PI3K/mTOR
pathway hyperactivation were not identified in the pretreatment sample, which
complements previous reports of HR+ female breast cancers being responsive to mTOR
inhibition without this activation. The postprogression sample, however, demonstrated
greater than fivefold increased estrogen receptor and pathogenesis-related protein
expression, which could have constrained the PI3K/mTOR pathway inhibition by BEZ235/
everolimus. Overall, these analyses have augmented the limited episteme on MBC
genetics and treatment.
[Supplemental material is available for this article.]
INTRODUCTION
The phosphatidylinositol-3-kinase (PI3K)/serine-threonine protein kinase AKT/mammalian
target of rapamycin (mTOR) signaling pathway plays a crucial role in several cellular
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functions, including growth, differentiation, survival, and metabolism. Aberrations of this
pathway are key drivers of carcinogenesis in many malignancies, and they are frequently im-
plicated in both primary and acquired resistance to anticancer targeted therapies, as well as
to cytotoxic agents and radiation (Burris 2013). In particular, the activation of the PI3K/AKT/
mTOR pathway has been indicated as a main mechanism of resistance to endocrine therapy
in hormone receptor (HR)-positive breast cancers, and several studies suggest a mutual
regulatory effect between PI3K/AKT/mTOR and estrogen receptor (ER) signaling (Ciruelos
Gil 2014).
The mTOR inhibitor everolimus (Afinitor/RAD001) was seen to significantly potentiate
the activity and efficacy of the steroidal aromatase inhibitor exemestane in patients with
HR+/HER2– advanced breast cancers refractory to nonsteroidal aromatase inhibitors
(Baselga et al. 2012; Piccart et al. 2014), and, thus, this combination has been approved
as first-line treatment for this setting. However, evidence indicates that the inhibition of
mTOR is not sufficient for achieving a complete blockade of the PI3K/AKT/mTOR pathway,
given the numerous regulatory loops that provide potential escape mechanisms (Efeyan and
Sabatini 2010).
BEZ235 inhibits class I PI3K molecules and both mTORC1 and mTORC2 complexes.
Preclinical models demonstrated that BEZ235 inhibited downstream molecules of
mTOR, classic rapamycin-induced AKT activation, and tumor growth in xenografts
(Maira et al. 2008). In dose-escalation trials of BEZ235, 20 of 27 patients undergoing
FDG-PET (fluorodeoxyglucose-positron emission tomography) imaging demonstrated a
decreased uptake, suggestive of some level of tumor shrinkage (Bendell et al. 2015).
Xu et al. (2011) first showed that everolimus and BEZ235 had a synergistic effect in
lung cancer cell lines and xenografts. Additional preclinical studies on multiple cancer
models, including breast cancer, have confirmed this synergy and that the combination
of subtherapeutic doses of everolimus synergized with BEZ235 to increase its potency
more than 10-fold (Nyfeler et al. 2012; Thomas et al. 2012; Passacantilli et al. 2014;
Leung et al. 2015).
In this report, we describe a male breast cancer patient who was treated with the ever-
olimus/BEZ235 combination therapy as third-line treatment for his metastatic disease and
experienced a prolonged stable disease. Therefore, we investigated molecular mechanisms
to explain the benefit and subsequent resistance to this combination treatment.
RESULTS
Clinical Presentation
A 66-yr-old Caucasian man underwent a right radical mastectomy and sentinel lymph node
biopsy for an infiltrative breast carcinoma of papillary histotype. Previous medical history in-
cluded hypertension, carotid atherosclerosis, and diabetes mellitus. There was no family his-
tory of breast cancer or other cancers. The tumor was pT1c, N0/1, M0, R0, G2, Ki67 15%,
ER+, PR+, HER2–. He started adjuvant tamoxifen treatment.
Two years later, multiple abnormal lymph nodes in the left axilla and a subcentimetric
lesion with malignant features in the left mammary gland were detected. The patient under-
went left radical mastectomy with axillary lymph node dissection (pretreatment sample).
Histology revealed a stage IIIa infiltrative ductal carcinoma, pT1a, N+ 9/11, R0, Ki67 8%,
ER+, PR+, HER2–. No distant metastases were detected. The patient was subsequently treat-
ed with standard adjuvant chemotherapy, consisting of four cycles of doxorubicin plus
paclitaxel every 3 wk; followed by four cycles of cyclophosphamide, methotrexate, and
5-fluorouracil every 4 wk; and 5 wk of radiotherapy. Subsequently, he started adjuvant
hormonotherapy with the nonsteroidal aromatase inhibitor letrozole.
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The patient developed multiple nodal and bilateral lung metastases 13 mo later. Fine-
needle aspiration was performed on the largest left axillary lymph node, confirming the
recurrence of ductal breast carcinoma. The patient started 12 courses of first-line chemother-
apy with vinorelbine plus capecitabine every 3 wk. Given the achievement of stable disease
control by radiological assessments, the patient was shifted to maintenance hormonother-
apy with high-dose estrogen receptor antagonist fulvestrant (500 mg i.m. every 4 wk).
After 8 mo, the left axillary nodal metastases progressed.
The patient was treated by an investigational combination of BEZ235 (200 mg orally,
twice daily) and subtherapeutic everolimus (2.5 mg orally, weekly). The combination therapy
was generally well tolerated, except for a G3 skin rash developed likely as a cumulative tox-
icity after 16 mo of treatment. Standard everolimus dosing is 10 mg daily, whereas 300 mg
b.i.d. is themaximum tolerated single-agent dose for BEZ235 (Bendell et al. 2015). The com-
bination treatment enabled sustained disease control for 18 mo.
When a newnodal metastasis occurred in the left infraclavicular region during continuous
BEZ235/everolimus combination treatment, this treatment was discontinued and the infra-
clavicular lymph node underwent surgical biopsy (postprogression sample). Immunohisto-
chemistry revealed the tumor as Ki67 10%–12%, ER+, PR+, and HER2–. The patient then
started endocrine therapy with the steroidal aromatase inhibitor exemestane. Sixteen
months later, a modest increase in the volume of left axillary lymph nodes was reported
on computed tomography (CT) scan. The clinical history is depicted in Figure 1.
Pharmacokinetics
A full pharmacokinetic (PK) profile of BEZ235 was collected from this patient with Cmax (peak
plasma concentration of the drug after administration), AUC (area under the curve), and T1/2
(elimination half-life) of 766 ng/mL, 6308 ng h/mL, and 5.53 h, respectively. The predose
trough concentration (Cmin) of BEZ235 in plasma after 200 mg b.i.d. observed over the study
period had values of 504, 262, 250, 75.4, and 363 ng/mL, respectively, for Period 1 Day 8
morning dose, Period 1 Day 8 evening dose, Period 2 Day 1 morning dose, Period 5 Day
1 morning dose, and Period 8 Day 1 morning dose. Everolimus Cmin after weekly administra-
tion was near or below the limit of detection of the analytical method as expected based on
the half-life of the drug of ∼30 hr.
Letrozole
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Figure 1. Clinical history of the patient. A 66-yr-old Caucasian man was diagnosed with infiltrative papillary
breast cancer. While on tamoxifen, he developed a contralateral infiltrative ductal breast carcinoma (pretreat-
ment sample). Following disease progression of his metastasis, he was treated with BEZ235 and everolimus.
Stable disease was maintained for 18 mo. Upon nodal metastasis, treatment was discontinued and the post-
progression sample collected.
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Genomic Analyses
Genomic analysis was undertaken to attempt to understand why this patient sustained pro-
longed stable disease to the BEZ235/everolimus combination treatment and to better char-
acterize male breast cancer (MBC), a rare disease (1% of all breast cancer cases). Therefore,
whole-exome sequencing and analysis was performed on the pretreatment and postpro-
gression samples and compared with a whole-blood normal control.
Overall, the tumors had few somatic alterations. Each tumor encoded 18 shared and nine
private somatic short variants (point mutations or indels; Table 1). All but two of the private
short variants (RNF212 p.L105S and FUBP1 p.W537∗) were determined to be subclonal after
adjusting for tumor purity and copy-number alterations. The tumors were also relatively sta-
ble at the chromosome level, sharing only a copy-number-neutral loss of heterozygosity in
Chromosome 1p, gain of Chromosome 16p, and loss of Chromosome 16q.
Although there was no family history of breast cancer, we examined BRCA1 and BRCA2
for genomic alterations given that the patient developed two histologically distinct cases of
breast cancer. No somatic alterations were detected in either gene, but three germline mis-
sense mutations were identified: BRCA1 p.Q309R, BRCA2 p.V2466R, and BRCA2 p.N372H.
None are clear breast cancer susceptibility loci; however, certain contradictory studies have
suggested that these BRCA2 polymorphisms may or may not confer increased risk (Cox et al.
2005; Palli et al. 2007; Cecener et al. 2014; Xue et al. 2014).
We assessed the mutations noted in Table 1 in the context of the targeted pathway and
previously reported alterations. No somatic mutations or copy-number variants were identi-
fied in genes encodingmembers of the PI3K/mTORpathway, such as PIK3CA, PTEN,MTOR,
TSC1, or TSC2. Gene or chromosomal region alterations previously uncovered by other
studies (Dawson et al. 1996; The Cancer Genome Atlas Network 2012; Deb et al. 2013),
such as TP53, KRAS, 8q gain, 11q gain, 17q gain, 20q gain, or 9q loss, were absent in this
patient. Only two of the identified short variants (point mutations or indels) were previously
reported in the COSMIC database, but with not more than two supporting records each.
Of the 36 total genes with point mutations or indels, only SLITRK6 and CACNA1C were
also mutated in the 10 MBC patients from the Cancer Genome Atlas (TCGA; The Cancer
Genome Atlas 2012); however, the impact of these genes on cancer is unclear.
Three of the somatic variants were of greater interest, however. One of the shared short
variants was a 16-bp frameshift deletion in theMsx2-bindingdomain ofSPEN, which encodes
a potential negative regulator of estrogen receptor (ER) transcriptional activity (Shi et al.
2001). Thepretreatment sample had aprivatenonsensemutation inFUBP1, a gene common-
ly mutated in lower-grade gliomas (The Cancer Genome Atlas Research Network 2015).
The postprogression sample also had a 9-megabase loss inChromosome12p (Supplemental
Fig. S1), which contains the tumor suppressor p27Kip1 (encoded by CDKN1B).
Protein Expression Analyses
To determine whether important signaling molecules were being regulated at the protein
level, immunohistochemistry (IHC) was performed on the pretreatment and postprogression
tumor samples (Supplemental Data). The examined signaling pathway biomarkers (HER2,
PTEN, pAKT, pS6-235/235, pS6-240/244, pMAPK, pMEK, and pEGFR) presented no or min-
imal expression changes between the two tumor specimens. These results suggest that
these proteins were noncontributory in the tumor’s resistance to the BEZ235/everolimus
combination therapy. Despite no differences between the time points, overall expression
of phosphorylated ribosomal protein S6 at Ser240/244, a downstream target of mTORC1,
in both samples was moderate (H-score 140).
Hormone receptor status was also evaluated for this patient. IHC indicated low ER/PR ex-
pression (ER 30% 1+; PR 20% 1+, 10% 3+) in the pretreatment sample, but expression levels
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of both receptors were increased (60% 1+) in the postprogression sample. Analysis of these
samples using the more quantitative Automated Quantitative Analysis (AQUA) IHC technol-
ogy platform verified a 10-fold score increase of ER from 31 to 312 and an almost fivefold
increase of PR from 271 to 1305 (Fig. 2).
DISCUSSION
MBC is a rare disease, with only 2350 estimated new cases and 440 deaths in the United
States in 2015, ∼1% of female breast cancer and <0.5% of male cancer overall (American
Cancer Society 2015). Because of its infrequency, the treatment and genetics of MBC is
not as well understood as for females.
Here we described a male breast cancer patient who received combination therapy of
the dual PI3K/mTOR inhibitor BEZ235 and low-dose everolimus as a third-line treatment
for his metastatic ductal carcinoma. This treatment yielded stable disease for 18 mo before
progression. Therefore, we chose to pursue genomic and immunohistochemical analyses to
understand themolecular mechanism of this sensitivity and subsequent resistance, as well as
the underlying genetics of MBC.
Because of the extended stable disease the patient sustained from the PI3K/mTOR inhib-
itors, wehadhypothesized thatgenomic and/or protein expression alterations in this pathway
would suggest a clear biological explanation. The results, though, did not suggest hyperac-
tivation of this pathway in the patient’s tumor prior to the BEZ235/everolimus combination
therapy. This lack of obvious hyperactivation could potentially be due to the pretreatment
sample being from initial diagnosis of the invasive ductal carcinoma, before the devel-
opment of detectable metastases and the several additional lines of therapy prior to the
combination treatment. However, previous research has demonstrated that PI3K pathway
Figure 2. AQUA quantitative immunohistochemistry showed a 10-fold increase in estrogen receptor (ER) (A)
and an almost fivefold increase in progesterone receptor (PR) (B) between the pretreatment and postprogres-
sion samples. HER2 expression remained negative in both samples. The graphs below the image display the
AQUA scores. The gray box indicates the cutoff, the green arrow, the pretreatment score, and the red arrow,
the postprogression score. Microscopy images at 40× magnification.
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alterations arenot necessary for response to PI3KormTOR inhibitors (Juric andBaselga2012;
Hortobagyi et al. 2015), reinforcing that the clinical benefit from PI3K or mTOR inhibition is
not dependent on PI3K pathway hyperactivation. Nevertheless, there was moderate expres-
sion of the mTORC1-specific phosphorylation of ribosomal protein S6, suggesting that this
pathway may be active in the tumors. Additionally, the tumor had a very quiet copy-number
profile, which has been associated in general with better prognosis (Ott et al. 2003; Burrell
et al. 2010; A’Hern et al. 2013). In the BOLERO-2 clinical trial in HR+/HER2−metastatic female
BC patients, patients with lower chromosomal instability had increased progression-free sur-
vival gain from everolimus treatment (Hortobagyi et al. 2015). Therefore, although there is no
clear genomic or protein biomarker explanation for the patient’s sensitivity to the BEZ235/
everolimus combination therapy, the patient’s HR positivity and chromosomal stability corre-
spond similarly with response to other PI3K or mTOR inhibition in female BC patients.
To explain the tumor’s subsequent resistance to the combination PI3K/mTOR inhibition,
genomic and histological examination revealed both the loss of a tumor suppressor and in-
creased expression of the hormone receptors as potential contributing factors. The loss of a
9-megabase region of Chromosome 12p in the postprogression tumor included the cell cy-
cle inhibitor p27Kip1, a protein normally inhibited by the PI3K pathway. Therefore, deletion
of one copy of the gene may have partially released the inhibition on cell proliferation that
occurred because of up-regulation of p27Kip1 from shutting down the PI3K pathway.
Supporting this notion, previous research has shown that the level of p27Kip1 expression
correlates with response to BEZ235 in mouse embryo fibroblasts (Lee et al. 2011).
Additionally, immunohistochemistry detected a five- to 10-fold increase in hormone recep-
tors in the postprogression sample, compared with the pretreatment sample. Resistance as-
sociated with an increase in hormone receptor levels has been seen in a number of patients
treated with a PI3Kα inhibitor, and in vitro work revealed that suppression of the PI3K path-
way increases transcription of ESR1 and expression of ER (Bosch et al. 2015). The patient’s
tumor’s renewed dependence on the hormone receptors is supported by further disease
control upon treatment with the aromatase inhibitor exemestane. Therefore, the decrease
of cell cycle inhibition combined with an increase in ER and PR levels may have been enough
to abrogate the effect of the PI3K/mTOR pathway blockade by BEZ235/everolimus.
To better understand the genomics of sporadic MBC, we profiled the patient’s pre-
treatment and postprogression tumors and found 27 short variants detected in each sample,
gain of Chromosome 16p, and loss of Chromosome 16q. No mutations were found in the
common breast cancer genes PIK3CA, TP53, CDH1, GATA3, or MAP3K1; no overlap was
discovered with common alterations from the 10 reported MBC cases by TCGA; and no
high-level amplifications of oncogenes were detected. Although the contribution of most
of the identified genomic alterations are unclear, the shared SPEN 16-bp frameshift deletion
may be biologically relevant: Previous research suggests that SPEN is a negative regulator of
ER transcriptional activity whose expression is increased in the presence of estradiol, creating
a potential self-regulatory loop for the estrogen response (Shi et al. 2001). The loss of func-
tion of this repressor could therefore potentially allow for increased ER transcriptional activity
in this ER-positive tumor. Additionally, the nonsense mutation in FUBP1 in the localized pre-
treatment tumor is interesting because loss-of-function mutations are common in lower-
grade gliomas (The Cancer Genome Atlas Research Network 2015); however, its role in
breast cancer is unknown. Overall, however, the relatively quiet genomes suggest that the
patient’s tumors could be driven by transcriptional, epigenetic, and/or cell signaling mech-
anisms, particularly those related to hormone receptors.
In conclusion, genomic and histological examination of this MBC patient with prolonged
stable disease while under BEZ235/everolimus combination treatment has given us further
insight into both MBC and response/resistance to this treatment. Additional studies will
be necessary to understand the role of FUBP1 inactivation in MBC and to confirm the
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hypothesis of decreased p27Kip1 expression and increased hormone receptor expression as
a mechanism of resistance to PI3K inhibitors.
METHODS
Clinical Assessment
The patient had tumor assessments by CT scan every 8 wk from the start of BEZ235/evero-
limus combination treatment until disease progression. The patient had weekly visits for clin-
ical examination during the first 8 wk of treatment; thereafter, the patient returned for visits
every 28 d.
Pharmacokinetics
A full PK profile of BEZ235 was collected in this patient at Cycle 1 Day 8. Concentration of
BEZ235 in plasma was determined by a LC-MS/MS (liquid chromatography–tandem mass
spectrometry) method following protein precipitation. The method has an LLOQ (lower limit
of quantification) of 2.0 ng/mL. Everolimus blood concentration in whole blood (K2 EDTA)
was determined by the LC-MS/MSmethod following solid-phase extraction. Themethod has
an LLOQof 0.300 ng/mL. PK parameters were calculated using noncompartmentalmethods.
Immunohistochemistry Assays
During treatment, formalin-fixed paraffin-embedded (FFPE) slides were stained and re-
viewed by a certified pathologist at the University of Verona. Pretreatment and postprogres-
sion results were further validated for this study. HER2 negativity was confirmed via IHC by
ARUP Laboratories. FFPE slides were stained and expression of Ki-67, pMAPK, pEGFR,
pMEK, pAKT, pS6-235/236, pS6-240/244, and PTENwas assessed by a certified pathologist.
ER and PR expression was confirmed and quantified using AQUA technology (Genoptix);
Fluorescent antibodies were bound, digitized using the slide-scanner system, andmeasured
based on nuclear expression in tumor cells.
Genomic Sequencing and Analysis
Tumor purity of pretreatment and postprogression tumor FFPE sections was pathologically
estimated at 85% and 75%, respectively. DNA was extracted from FFPE and whole-blood
control samples using the Promega Maxwell DNA extraction kit. Libraries were constructed
using Illumina TruSeq, captured with the Agilent SureSelect Whole Exome V4 baits
and protocol, and sequenced on an Illumina HiSeq 2500 as 100-bp paired-end reads.
Resulting FASTQ files were aligned to the hg19 reference genome using BWA-MEM (Li
2013), duplicates weremarkedwith Picard (http://broadinstitute.github.io/picard/), and local
realignment and base quality recalibration were performed with GATK (Genome Analysis
Toolkit;McKennaet al. 2010;DePristoet al. 2011). Resultingmean target coverageof thepre-
treatment and postprogression FFPE tumor specimens were 142× and 179×, respectively
(Table 2). The whole-blood control normal control was purposely sequenced to a lower cov-
erage of 82×.
Table 2. Sequencing metrics
Sample Total reads Unique mapped reads Mean target coverage
Pretreatment 118,318,058 92,907,513 142
Postprogression 137,438,824 120,704,547 179
Normal 59,691,734 56,623,598 82
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Single-nucleotide variants were called in paired normal mode using MuTect (Cibulskis
et al. 2013) and phased with GATK, whereas indels were called with Pindel (Ye et al.
2009) and filtered against a pool of normal samples. Annotation was performed with
SnpEff (Cingolani et al. 2012), using dbSNP v141 (http://www.ncbi.nlm.nih.gov/SNP/),
COSMIC v70 (Forbes et al. 2015), and dbNSFP v2.4 (Liu et al. 2013). Nonsynonymous pro-
tein-coding SNVs or indels with coverage of at least 10× or 30×, respectively, in at least one
tumor sample were retained. All calls were manually reviewed in IGV (Integrative Genomics
Viewer; Robinson et al. 2011). Copy number, tumor purity, loss of heterozygosity, and sub-
clonality were performed using an in-house implementation, the ABSOLUTE algorithm
(Carter et al. 2012), after the GC normalization step from Control-FREEC (Janevski et al.
2012). Tumor purity was calculated to be 47% in the pretreatment sample and 72% in the
posttreatment sample. Common alterations in the 10 MBC patients from the BRCA TCGA
study were accessed via the Breast Invasive Carcinoma (TCGA, Provisional) data set at
http://cBioPortal.org (Cerami et al. 2012; Gao et al. 2013).
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